NEOV vs ULBI
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
NEOV exhibits severe financial distress as evidenced by a critical Piotroski F-Score of 1/9, indicating fundamental weakness across almost all health metrics. While the company shows explosive revenue growth (333.5%), this is not translating into profitability, with an operating margin of -96.36% and a disastrous ROE of -238.01%. The valuation is disconnected from fundamentals, trading at a Price/Book ratio of 22.39 and a Forward P/E of 309.00. The combination of consistent earnings misses and a bearish technical trend suggests a high-risk speculative profile.
ULBI presents a contradictory profile: a stable Piotroski F-Score of 6/9 and strong liquidity are offset by deteriorating profitability and severe earnings misses. While the stock trades attractively on a Price-to-Book (0.99) and Price-to-Sales (0.68) basis, the negative profit margins and a high PEG ratio (3.81) suggest that the recent price surge is disconnected from fundamental earnings growth. The company's stability is anchored by a low Debt/Equity ratio (0.41), but high customer concentration and consistent EPS underperformance create significant risk.
Compare Another Pair
Related Comparisons
NEOV vs ULBI: Head-to-Head Comparison
This page compares NeoVolta Inc. (NEOV) and Ultralife Corporation (ULBI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.